Zevra Therapeutics (ZVRA) Net Margin (2016 - 2025)
Historic Net Margin for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 2.08%.
- Zevra Therapeutics' Net Margin rose 8958900.0% to 2.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.85%, marking a year-over-year increase of 4079100.0%. This contributed to the annual value of 446.85% for FY2024, which is 2791600.0% down from last year.
- Zevra Therapeutics' Net Margin amounted to 2.08% in Q3 2025, which was up 8958900.0% from 288.44% recorded in Q2 2025.
- Zevra Therapeutics' 5-year Net Margin high stood at 288.44% for Q2 2025, and its period low was 1849.38% during Q2 2022.
- In the last 5 years, Zevra Therapeutics' Net Margin had a median value of 230.2% in 2022 and averaged 316.87%.
- In the last 5 years, Zevra Therapeutics' Net Margin tumbled by -17601600bps in 2022 and then surged by 18190100bps in 2023.
- Quarter analysis of 5 years shows Zevra Therapeutics' Net Margin stood at 104.69% in 2021, then tumbled by -326bps to 446.14% in 2022, then skyrocketed by 65bps to 153.96% in 2023, then crashed by -93bps to 297.53% in 2024, then soared by 99bps to 2.08% in 2025.
- Its Net Margin was 2.08% in Q3 2025, compared to 288.44% in Q2 2025 and 15.19% in Q1 2025.